GlassScriptPhysician profile
Glenn Brauntuch
NPI 1821012071
$5,223.16
in general payments reported to CMS, 2019-2025
54 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $612 · 2021: $819 · 2022: $754 · 2023: $712 · 2024: $511 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $808.83 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.21 | 2019-2024 | Ofev, Synjardy, Jardiance |
| Amgen INC. | $306.40 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $292.51 | 2019-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $192.37 | 2019-2025 | Keytruda |
| Mannkind Corporation | $176.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $165.37 | 2019-2020 | |
| Shire North American Group INC | $163.38 | 2019 | |
| Mylan Specialty L.P. | $153.97 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $151.66 | 2019-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $149.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $147.77 | 2019-2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $134.95 | 2020-2024 | Glassia, Aralast |
| Abbvie INC. | $116.37 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $114.80 | 2021-2025 | Acthar |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Brauntuch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.